Stages in LAV/HTLV-III lymphadenitis. II. Correlation with clinical and immunological findings.
The aim of the present study was to investigate the relation between the histopathological findings in LAV/HTLV-III lymphadenitis and immunological, clinical, and serological variables. The study group included 38 consecutive homosexual men with persistent generalized lymphadenopathy (PGL) in whom lymph node biopsy was performed. The histopathological lymph node changes were grouped into three stages. Opportunistic infections at the time of biopsy and their development during follow-up were significantly associated with stage III histology (follicular depletion). Analysis of blood from 10 patients with stage III histology revealed significantly (P less than 0.01) decreased proliferative responses of lymphocytes to mitogens and reduced absolute number of CD5+ and CD4+ lymphocytes compared with 17 patients with stage I histology (follicular hyperplasia), whereas patients with stage II histology (follicular involution) had intermediate values. The absolute number of CD8+ lymphocytes was increased in all three stages, as was IgG, while increase in IgM and IgA was restricted to stage III. No difference was observed between the different histopathological stages with respect to the specificity of the anti-LAV/HTLV-III antibody as measured by immunoblotting. In conclusion, the defects of lymphocytes from the blood of LAV/HTLV-III infected persons reflect alterations in secondary lymphoid tissue. Further, there is a close correlation between these alterations and the clinical status of the patients.
D000163:Acquired Immunodeficiency Syndrome / Q000097:blood / Q000276:immunology / Q000473:pathology*; D001706:Biopsy; D006716:Homosexuality; D006801:Humans; D007136:Immunoglobulins / Q000032:analysis; D008198:Lymph Nodes / Q000473:pathology*; D008199:Lymphadenitis / Q000097:blood / Q000276:immunology / Q000473:pathology*; D008213:Lymphocyte Activation; D008214:Lymphocytes / Q000145:classification / Q000276:immunology; D008297:Male; D011379:Prognosis
D007136:Immunoglobulins